ArticleEuropean urology2022

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.

Anirban P Mitra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.